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Summary: Determination of the functional hepatic reserve is still controversial. Many tests have been proposed,
but the assay based on formation of the lidocaine metabolite, monoethylglycine xylidide, seems to offer a
promising approach to this problem. In this study we evaluated the effectiveness of the monoethylglycine
xylidide test in the clinical evaluation of 31 cirrhotic patients submitted to three different therapeutic options
(sclerotherapy, transjugular intrahepatic portosystemic shunt and surgical procedures) and in 1 patient
submitted to right hepatectomy for giant hepatic angioma. We found a statistically significant difference
between Child A and C patients and between Child B and C patients. The test did not differentiate Child A
from Child B patients. We found no correlation between the Child-Pugh score, serum bilirubin, albumin and
prothrombin time. There were no differences among the three groups of patients that could be statistically
related to their therapy. The monoethylglycine xylidide test seems to be an attractive alternative to previous
methods for the evaluation of the functional hepatic reserve, but further studies are necessary to assess the
prognostic value of the test in cirrhotics, to separate the independent contribution of portosystemic shunting
and hepatocyte dysfunction to monoethylglycine xylidide formation, and to evaluate the test as a prognostic
index in cirrhotic patients submitted to general surgery.
Introduction , ,
 x , , . . . ..... ^ A .onstrated that the monoethylglycine xylidide test in
It is difficult to evaluate the functional hepatic reserve liver donors gives prognostic information on the graft
in the cirrhotic patient. Conventional static liver func- survival in the corresponding recipients (4 — 6), and
tion tests lack specificity in predicting disease severity, may also be suitable for transplant candidate rating
and dynamic liver function tests could be an attractive and post-transplant follow-up (7 — 10), even in chil-
alternative to traditional methods (1). In previous dren (11, 12).
papers, the lidocaine metabolite, monoethylglycine _,
 r . 4 A , * j * · *uf . , " ' - , , . ' . . . j. ^ The aim of the present study was to determine the
xylidide was reported to be a highly sensitive indicator
 rr . - f , . . . ..... . . .ΓΙ, *· Λ Ϊ *· /^ o\ etfec veness of the monoethylglycine xylidide test in
of hepatic dysfunction (2,3). , ,. · , , · * · ί - .· \ ^ ·<.* Λthe clinical evaluation of cirrhotic patients submitted
Monoethylglycine xylidide is formed from lidocaine to sclerotherapy, transjugular intrahepatic portosys-
by oxidative N-deethylation by the hepatic cyto- temic shunt and general surgery, compared with the
chrome P-450 system (1 —4). Prospective studies dem- CMld-Pugh classification and score.
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Materials and Methods
Between January 1991 and September 1992 we performed the
monoethylglycine xylidide test in 41 cirrhotic patients admitted
to our surgical unit. Nine patients with monoethylglycine xy-
lidide concentrations above 15 μπιοΐ/ΐ due to previous Hdocaine
treatment were excluded from this study. One patient was
affected by a giant hepatic angioma, and all the remaining
patients suffered from histologically confirmed liver cirrhosis
(tab. 1). Alcohol was the aetiology of liver cirrhosis in most
cases (22 cases), 6 patients had posthepatitic cirrhosis, 2 had
cryptogenic cirrhosis and 1 had biliary cirrhosis.
Tab. 1. Demographic data of the patients
- Age
- Sex
range:
mean:
females:
males:
29-79 years
57.4 years
10
22
Sixteen patients (50%) were referred to our department for
bleeding gastrp-oesophageal varices (Group 1). In these patients
bleeding was controlled by endoscopic sclerotherapy.
Eight patients (25%) (Group 2) were submitted to transjugular
intrahepatic portosystemic shunt (see tab. 2) for bleeding re-
currence from gastro-oesophageal varices (5 patients), ascites
not responsive to medical therapy (2 patients), or reduction of
portal hypertension in view of total oesophagectomy for oes-
ophageal carcinoma (1 patient).
Eight patients (25%) (Group 3) were referred to us for surgical
evaluation. Table 3 shows the patient group 3 with the diag-
nosis, the performed operation, the postoperative outcome and
the follow-up.
All of the patients were submitted to the normal liver function
tests and all of the 31 cirrhotic patients were classified according
to Child-Pugh criteria (13): this classification includes ascites,
encephalopathy, serum bilirubin, albumin and prothrombin
time.
In the first group of patients,
4 were class A (Child-Pugh score ranging between 5 and 6),
7 were class Β (score between 7 and 9) and
5 were class C (score between 10 and 15).
In the second group, f
1 patient was Child A,
4 patients were Child Β and
3 patients were Child C.
In the third group,
1 patient was class A and
6 patients were class B.
In this latter group we enrolled a non-cirrhotic female receiving
a right hepatectomy for giant hepatic angioma.
Venous blood samples for monoethylglycine xylidide determi-
nation were collected before and 15, 30 and 60 minutes after a
single intravenous bolus of Hdocaine hydrochloride (1 mg/kg)
injected over a period of 2—4 minutes. Monoethylglycine xy-
lidide was determined in serum by the TDx fluorescence polar-
ization immunoassay system (Abbott Laboratories, Chicago,
IL, USA).
The significance of differences between groups was determined
by one-way ANOVA, and groups of data were compared using
the Snedecor F test.
Results
Monoethylglycine xylidide concentrations in all pa-
tients at 15, 30 and 60 minutes are shown in figure 1.
The monoethylglycine xylidide concentrations at 30
minutes in patient group 1 (sclerotherapy) ranged
between < 6 μιηοΐ/l and 62 μιηοΐ/ΐ. In this group,
monoethylglycine xylidide concentrations at 30 min-
utes ranged between 8 and 31 in Child-Pugh class A,
between 7 and 62 in class 6 and between < 6 and 22
μιηοΐ/ΐ in class C.
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Fig. 1. Monoethylglycine xylidide values in the three patient groups at 15, 30 and 60 min after intravenous lidocaine bolus.
B 15 mm 0 30 min g 60 min
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In group 2 transjugular intrahepatic portosystemic
shunt the 30 minutes monoethylglyeine xylidide con-
centrations ranged between 6 and 62 μιηοΙ/1. Mono-
ethylglyeine xylidide concentrations at 30 minutes,
before the procedure, were 6 μιηοΐ/l in the single Child
A patient, and they ranged between 18 and 62 in the
class Β patients and between 6 and 17 μηιοΐ/ΐ in the
class C patients. We compared these results with those
obtained three months after the transjugular intra-
hepatic portosystemic shunt and found no significant
differences in monoethylglyeine xylidide concentra-
tions (t value = 1.07; ρ = 0.32). The results obtained
in this group of patients are summarized in table 2.
In patient group 3 (operated) the monoethylglyeine
xylidide concentrations at 30 minutes ranged between
2 and 23 μιηοΐ/ΐ for Child Β patients. The single Child
A patient had a monoethylglyeine xylidide value of
86 μιηοΐ/ΐ. In the non-cirrhotic patient with giant
hepatic angioma the 30 min monoethylglyeine xyli-
dide concentration was 58 μπιοΙ/1. The results ob-
tained in this third group of patients are summarized
in table 3, where the outcome and the follow-up of
single patients is also reported.
Discussion
The goal of this study was to investigate the effect-
iveness of the monoethylglyeine xylidide test in pre-
dicting the functional hepatic reserve in cirrhotic pa-
tients submitted to three different therapeutic options.
We did not find any statistical difference in mono-
ethylglyeine xylidide concentrations in the samples at
15, 30 and 60 minutes (see tab. 4); as also stated by
other authors (1 —4), we think the monoethylglyeine
xylidide determination at 30 minutes is sufficient for
determination of the functional hepatic reserve in
cirrhotic patients. We found a statistically significant
difference between Child A and C patients and be-
tween Child Β arid C patients (F = 2.06; ρ < 0.05).
On the basis of the monoethylglyeine xylidide we
could not differentiate Child A from Child Β patients
(mean values 29 μηιρί/ΐ for both), or find any corre-
lation with the Child-Pugh score (see tab. 5). The
monoethylglyeine xylidide test identified the Child C
better than Child A or Β patients. In all the patients
there was no statistical correlation between the mono-
ethylglyeine xylidide concentrations at 30 minutes and
the values of serum bilirubin, albumin and pro throm-
bin time. In table 5 the concentrations of bilirubin,
albumin, prothrombin time and Pugh score are sum-
marized with the statistical evaluation.
There were no statistical differences in monoethylgly-
eine xylidide values in the three groups of patients
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Tab. 3. Patient group 3 (operated) with post-operative outcome and follow-up
Patient Age Sex Child- Child- Mono- Diagnosis Performed
(a) Pugh Pugh ethyl- operation
classi- score glycine
fication xylidide
30 min
(μΐΏθΙ/1)
Post-operative Follow-up
outcome
(30 days)
M. A.
M. C.
Gl. L.
V. L.
F.D.
P. V.
M. G.
0. B.
63 <f
71 cJ
52 ?
51 ?
61 6"
64
 0
A
63 c?
52 §
A
B
B
B
B
B
B
—
5
7
9
9
7
7
8
—
86
18
23
2
9
14
8
58
Lung cancer
Cardial cancer
Gastric cancer
Hepato-cellular
carcinoma
Hypersplenism
Oesophageal
cancer
Hepato-cellular
carcinoma
Adenocarcinoma
Vater's ampulla
Giant hepatic
angioma
Explorative
thoracotomy
Total
gastrectomy
Subtotal
gastrectomy
Segmentectomy +
Splenectomy
Total
oesophagectomy
Segmentectomy
Local
excision
Right
hepatectomy
Uneventful
Uneventful
Complicated
by infected
ascites
Died from
hepatic failure
Uneventful
Uneventful
Died from
hepatic failure
Uneventful
Died at
2 months
Alive at
20 months
Alive at
18 months
—
Alive at
19 months
Alive at
5 months
-
Alive at
4 months
Tab. 4. Mean values of monoethylglycine xylidide 15, 30 and
60 min after administration of the lidocaine bolus
Monoethylglycine xylidide, mean (umol/1)
Group 1
Group 2
Group 3
15 min 30 min 60 min
20 25 28
p = 0.46 p = 0.67
p = 0.24
21 25
I I I
31
p = 0.71 p = 0.56
23l
l
p = 0.36
31
I I
p = 0.56 p = 0.98
32|
p = 0.53
that could be statistically related to their therapy.
Moreover, in the second group of patients, we eval-
uated the 30 minutes monoethylglycine xylidide con-
centrations before and three months after transjugulaf
intrahepatic portosystemic shunt, i.e. from a hae-
modynamic point of view, a side-to-side portocaval
shunt; the monoethylglycine xylidide concentrations
ranged between 6 and 62 μιηοΐ/l before transjugular
intrahepatic portosystemic shunt and between 10 and
32 after transjugular intrahepatic portosystemic
shunt. From literature data (1, 3), we know that in
hepatic cirrhosis the formation of monoethylglycine
xylidide is decreased by both portosystemic shunting
and hepatocyte dysfunction, but we were not able to
differentiate the independent contribution of porto-
systemic shunting and impaired hepatocyte activity.
Of all the 32 patients, 4 died during a follow-up period
ranging from 2 to 19 months. One of these died of
cancerous cachexia, the other 3 of liver failure; these
3 patients had 30 min irioiioethylglycine xylidide con-
centrations < 8 μηιοΐ/ΐ, but the patient number is too
small for a statistically relevant prognostic conclusion.
In conclusion, the monoethylglycine xylidide test is
quick and easy to perform, it does not require serial
blood sample collection but only two specimens of
about 1 ml, monoethylglycine xylidide concentrations
can be measured within 20 minutes, and the low doses
of lidocaine used appear to be safe (1, 5). The mono-
ethylglycine xylidide liver function test seems to be a
promising approach to the evaluation of the func-
tional hepatic reserve in cirrhotic patients. Another
interesting use of the monoethylglycine xylidide test
could be the preoperative assessment of cirrhotic pa-
tients prior to general surgery. A larger number of
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Tab. 5. Statistical comparison of monoethylglycine xylidide with the mean concentrations of bilirubin, albumin and prothrombin
time in the three groups of patients
Group 1
Group 2
Group 3
Classification
Child A
Child B
Child C
Child A
Child B
Child C
Chad A
Child B
Chud C
Bilirubin
'(iimol/l)
15
24
43
13
22
67
25
25
Albumin
(g/1)
38
33
24
35
28
26
36
25
Pro-
thrombin
time
(%)
64
58
58
80
58
52
97
70
Score vs
Monoethyl-
glycine
xylidide
(P)
0.89
0.75
0.80
Monoethylglycine
xylidide vs bilirubin,
albumin,
prothrombin
time (p)
0.99, 0.35, 0.95
0.87, 0.31, 0.93
0.63,0.11,0.61
patients is needed to evaluate this aspect of the mono-
ethylglycine xylidide test.
Further prospective studies are necessary to fully as-
sess the prognostic value of the test in cirrhotics and
to separate the independent contribution of portosys-
temic shunting and hepatocyte dysfunction in mono-
ethylglycine xylidide formation. It may then be pos-
sible to use the test as a predictor of mortality and
morbidity, and to assess the extent of intra- and
extrahepatic shunting in cirrhotic patients.
References
1. Oellerich, M., Burdelski, M., Lautz, H. U., Schulz, M.,
Schmidt, F. W. & Herrmann, H. (1990) Lidocaine metab-
olite formation as a measure of liver function in patients
with cirrhosis. Then Drug Monit. 12, 219-226.
2. Oellerich, M., Burdelski, M., Lautz, H. U, Rodeck, B.,
Duewel, J., Schulz, M., Schmidt, F. W., Brodehl, J. &
Pichlmayr, R. (1991) Assessment of pretransplant prognosis
in patients with cirrhosis. Transplantation 51, 801 — 806.
3. Oellerich, M., Räude, E., Burdelski, M., Schulz, M.,
Schmidt, F. W., Ringe, B., Lamesch, P., Lamesch, P., Pichl-
mayr, R., Raith, H., Scheruhn, M., Wrenger, M. & Witte-
kind, Ch. (1987) Monoethylglycinexylidide formation ki-
netics: A novel approach to assessment of liver function. J.
Clin. Chem. Clin. Biochem. 25 845-853.
4. Layrargues, G. P., Huet, P. M., Infante-Rivard, C., Ville-
neuve, J. P., Marleau, D., Duguay, L., Tanguay, S. &
Lavoie, P. (1988) Prognostic value of indqcyanine green
and lidocaine kinetics for survival and chronic hepatic
encephalopathy in cirrhotic patients following elective end-
to-side portocaval shunt. Hepatology 8 (6), 1506—1510.
5. Schroeder, T. J., Gremse, D. A., Mansour, M. E., Theuer-
ling, A. W., Brunson, M. E., Ryckman, F. C., Suchy, F. J.,
Penn, ., Alexander, J, W., Pesce, A. J., First, M. R. &
Balistreri, W. F. (1989) Lidocaine metabolism as an index
of liver function in hepatic transplant donors and recipients.
Transplant. Prop. 27, 229-2301.
6. Oellerich, M., Ringe, B., Gubernatis, G., Pichlmayr, R.,
Burdelski, M., Lamesch, P., Bunzendhal, H. & Herrmann,
H. (1989) Ligrjiocaine metabolism formation as a measure
of pre-trajispiant iiver function. Lancet i, 640—642.
7. Oellerich, M., Burdelski, M., Lautz, H. U, Binder, L. &
Pichlmayr, R. (1991) Predictors of one-year pretransplant
survival in patients with cirrhosis. Hepatology 14, 1029 —
1034.
8. Lamesch, P., Ringe, B., Oellerich, M., Burdelski, M., Bey-
rau, R., Gubernatis, G. & Pichlmayr, R. (1990) Assessment
of liver function in the early postoperative period after liver
transplantation with ICG, MEGX and GAL tests. Trans-
plant. Proc. 22, 1539-1541.
9. Oellerich, M., Burdelski, M., Beyrau, R., Ringe, B., La-
mesch, P., Wonigeit, K., Lautz, H. U, Gubernatis, G., Taki,
Y. & Pichlmayr, R. (1989) Lidocaine metabolite formation
as a measure of early post-transplant liver function. He-
patology 10, 625.
10. Oellerich, M., Burdelski, M., Lautz, H. U, Räude, E.,
Ringe, B., Lamesch, P., Gubernatis, G., Beneking, M.,
Rodeck, B. & Pichlmayr, R. (1988) Efficiency of the MEGX
formation test in liver transplantation. Hepatology 8, 1220.
11. Gremse, D. A., Schroeder, T J. & Balistreri, W. F. (1988):
Assessment of lidocaine metabolism as a quantitative liver
function test in children. Hepatology 8, 1382.
12. Gremse, D. A., -Kader, H. H., Schroeder, T. J. & Balis-
treri, W. F. (1990) Assessment of lidocaine metabolite for-
mation as a quantitative liver function test in children.
Hepatology 72, 565-569.
13. Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L.,
Pietroni, M. G. & Williams, R. (1973) Transection of the
oesophagus for bleeding oesophageal varices. Br. J. Surg.
60, 646-649.
Dr. Michele Schinella
Laboratorio di Chimica Clinica ed Ematologia
Ospedale Civile Maggiore
P. le A. Stefani 1
1-37126 Verona
Italia
Bur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 9

